A phase I/II study of AIM ACT for patients with acute myeloid leukemia and/or myelodysplastic syndromes who have relapsed after an allogeneic hematopoietic stem cell transplant

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs AIM ACT (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use

11 Dec 2018 According to a NexImmune media release, the company plans to advance its AIM ACT platform into this early phase clinical trial in 2019.
02 Jan 2018 According to a NexImmune media release, the company is planning to initiate the trial in 2018.
20 Oct 2017 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com